Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 2
2019 1
2020 2
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Radiotheranostic Agents in Hematological Malignancies.
Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D'Huyvetter M. Caers J, et al. Among authors: lejeune m. Front Immunol. 2022 Jul 5;13:911080. doi: 10.3389/fimmu.2022.911080. eCollection 2022. Front Immunol. 2022. PMID: 35865548 Free PMC article. Review.
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Lejeune M, et al. Front Immunol. 2020 May 7;11:762. doi: 10.3389/fimmu.2020.00762. eCollection 2020. Front Immunol. 2020. PMID: 32457743 Free PMC article. Review.
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma.
Lejeune M, Köse MC, Jassin M, Gou MJ, Herbet A, Duray E, Cobraiville G, Foguenne J, Boquet D, Gothot A, Beguin Y, Fillet M, Caers J. Lejeune M, et al. Hemasphere. 2023 Jun 22;7(7):e901. doi: 10.1097/HS9.0000000000000901. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37359190 Free PMC article.
[What is new in the management of multiple myeloma].
Vrancken L, Muller J, Lejeune M, Gregoire C, Delens L, Jaspers A, Servais S, Prijck B, Baron F, Caers J, Beguin Y. Vrancken L, et al. Among authors: lejeune m. Rev Med Suisse. 2018 Aug 22;14(615):1438-1442. Rev Med Suisse. 2018. PMID: 30136458 French.
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
Muller J, Bolomsky A, Dubois S, Duray E, Stangelberger K, Plougonven E, Lejeune M, Léonard A, Marty C, Hempel U, Baron F, Beguin Y, Cohen-Solal M, Ludwig H, Heusschen R, Caers J. Muller J, et al. Among authors: lejeune m. Haematologica. 2018 Aug;103(8):1359-1368. doi: 10.3324/haematol.2017.185397. Epub 2018 May 10. Haematologica. 2018. PMID: 29748441 Free PMC article.
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Bolomsky A, Muller J, Stangelberger K, Lejeune M, Duray E, Breid H, Vrancken L, Pfeiffer C, Hübl W, Willheim M, Weetall M, Branstrom A, Zojer N, Caers J, Ludwig H. Bolomsky A, et al. Among authors: lejeune m. Br J Haematol. 2020 Sep;190(6):877-890. doi: 10.1111/bjh.16595. Epub 2020 Mar 30. Br J Haematol. 2020. PMID: 32232850 Free article.